Parameter Set Mycophenolic Acid - LC-MS/MS

Order No.: 92916
Parameters:
Mycophenolic Acid, Mycophenolic Acid Glucuronide

For the analysis of MPA and MPAG
3PLUS1® and 6PLUS1® Multilevel Calibrator Sets available
Part of the continuously updated MassTox® TDM Series A
Sample preparation with 96 well filter plates also possible

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR 2017/746

Mycophenolic Acid

Mycophenolic Acid Glucuronide

Clinical relevance

Mycophenolic acid (MPA) is used as an immunosuppressant agent to prevent organ transplant rejection. MPA selectively inhibits the synthesis of purines and specifically reduces the growth of B- and T-lymphocytes. Furthermore, MPA is also used to treat autoimmune diseases such as psoriasis, systemic lupus erythematosus or scleroderma.

Therapeutic monitoring of MPA in the blood is required to adjust individual concentrations within the therapeutic window and to attain a favourable ratio between therapeutic effects and side effects. Currently available drugs contain mycophenolate mofetil or mycophenolate sodium, which are both completely metabolised into the active metabolite MPA. For excretion, MPA is bound to glucuronic acid.

This parameter set allows the quantitative determination of mycophenolic acid and its metabolite mycophenolic acid glucuronide in human serum or plasma samples by LC-MS/MS (liquid chromatography mass spectrometry).
It is intended as a monitoring test for patients treated with mycophenolate mofetil or mycophenolate sodium as an aid to ensure drug levels are maintained within the therapeutic range.

 

MassTox® TDM Serie A

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory.
It consists of:
• MassTox® TDM Basic Kit A
• Specific MassTox® TDM Parameter Set (13 different parameter sets available)
• Analytical column MassTox® TDM MasterColumn® A

More information about MassTox® TDM Series A

 

MassSTAR

For this parameter set a CE-IVD compliant workflow method is also available using the MassSTAR to automate the sample preparation.

More information about MassSTAR

More Information
Method of Analysis LC-MS/MS
Please note The information listed here, including the sample preparation, is not sufficient for using the product. Please read the information provided in the instruction manual, which includes detailed information on limitations associated with the use of the product in line with its intended purpose. Detailed performance evaluation data for this assay can be found in Appendices II and III of the instruction manual.
Lower and Upper Limit of Quantitation

MPA: 0.2 – 75 mg/l
MPAG: 2.5 – 500 mg/l

Different systems might show different performance data.

Specimen Serum/Plasma
Sample Preparation

The information on the sample preparation presented here is not sufficient for use in the laboratory. For a detailed step by step description, please refer to the instruction manual.

  • Reconstitute the Internal Standard Mix
  • Add 800 μl Internal Standard mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 1.8 min
Injection Volume 0.2 – 50 µl (mass spectrometer dependent)
Gradient binary
Ionisation ESI positive
MS/MS Mode MRM
Parameters Mycophenolic Acid, Mycophenolic Acid Glucuronide
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.

Mycophenolic Acid

Mycophenolic Acid Glucuronide

Clinical relevance

Mycophenolic acid (MPA) is used as an immunosuppressant agent to prevent organ transplant rejection. MPA selectively inhibits the synthesis of purines and specifically reduces the growth of B- and T-lymphocytes. Furthermore, MPA is also used to treat autoimmune diseases such as psoriasis, systemic lupus erythematosus or scleroderma.

Therapeutic monitoring of MPA in the blood is required to adjust individual concentrations within the therapeutic window and to attain a favourable ratio between therapeutic effects and side effects. Currently available drugs contain mycophenolate mofetil or mycophenolate sodium, which are both completely metabolised into the active metabolite MPA. For excretion, MPA is bound to glucuronic acid.

This parameter set allows the quantitative determination of mycophenolic acid and its metabolite mycophenolic acid glucuronide in human serum or plasma samples by LC-MS/MS (liquid chromatography mass spectrometry).
It is intended as a monitoring test for patients treated with mycophenolate mofetil or mycophenolate sodium as an aid to ensure drug levels are maintained within the therapeutic range.

 

MassTox® TDM Serie A

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory.
It consists of:
• MassTox® TDM Basic Kit A
• Specific MassTox® TDM Parameter Set (13 different parameter sets available)
• Analytical column MassTox® TDM MasterColumn® A

More information about MassTox® TDM Series A

 

MassSTAR

For this parameter set a CE-IVD compliant workflow method is also available using the MassSTAR to automate the sample preparation.

More information about MassSTAR

More Information
Method of Analysis LC-MS/MS
Please note The information listed here, including the sample preparation, is not sufficient for using the product. Please read the information provided in the instruction manual, which includes detailed information on limitations associated with the use of the product in line with its intended purpose. Detailed performance evaluation data for this assay can be found in Appendices II and III of the instruction manual.
Lower and Upper Limit of Quantitation

MPA: 0.2 – 75 mg/l
MPAG: 2.5 – 500 mg/l

Different systems might show different performance data.

Specimen Serum/Plasma
Sample Preparation

The information on the sample preparation presented here is not sufficient for use in the laboratory. For a detailed step by step description, please refer to the instruction manual.

  • Reconstitute the Internal Standard Mix
  • Add 800 μl Internal Standard mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 1.8 min
Injection Volume 0.2 – 50 µl (mass spectrometer dependent)
Gradient binary
Ionisation ESI positive
MS/MS Mode MRM
Parameters Mycophenolic Acid, Mycophenolic Acid Glucuronide
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.